Regeneron Pharmaceuticals, Inc. $REGN Stake Increased by Illinois Municipal Retirement Fund

Illinois Municipal Retirement Fund grew its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 3.9% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 31,884 shares of the biopharmaceutical company’s stock after buying an additional 1,209 shares during the quarter. Illinois Municipal Retirement Fund’s holdings in Regeneron Pharmaceuticals were worth $24,177,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in REGN. Orbimed Advisors LLC purchased a new stake in Regeneron Pharmaceuticals during the first quarter valued at about $11,358,000. BlackRock Inc. bought a new stake in Regeneron Pharmaceuticals during the second quarter worth about $5,682,636,000. Contravisory Investment Management Inc. bought a new stake in Regeneron Pharmaceuticals during the second quarter worth about $6,327,000. Oxbow Advisors LLC purchased a new position in shares of Regeneron Pharmaceuticals in the 2nd quarter worth about $3,342,000. Finally, Compass Financial Management LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 4,526.2% in the 3rd quarter. Compass Financial Management LLC now owns 3,007 shares of the biopharmaceutical company’s stock worth $2,280,000 after purchasing an additional 2,942 shares in the last quarter. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Price Performance

REGN opened at $916.06 on Wednesday. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.35 and a quick ratio of 2.89. Regeneron Pharmaceuticals, Inc. has a 1 year low of $591.52 and a 1 year high of $991.73. The firm has a market cap of $94.77 billion, a price-to-earnings ratio of 19.26, a PEG ratio of 1.22 and a beta of 0.10. The stock’s 50 day simple moving average is $809.24 and its 200 day simple moving average is $744.46.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Friday, October 30th. The biopharmaceutical company reported $20.07 EPS for the quarter, beating analysts’ consensus estimates of $16.51 by $3.56. Regeneron Pharmaceuticals had a net margin of 28.51% and a return on equity of 16.01%. The company had revenue of $5.12 billion during the quarter, compared to analyst estimates of $4.58 billion. During the same period in the prior year, the business posted $11.83 EPS. The firm’s revenue was up 36.3% compared to the same quarter last year. As a group, analysts predict that Regeneron Pharmaceuticals, Inc. will post 58.26 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, December 3rd. Stockholders of record on Friday, November 20th will be issued a dividend of $0.94 per share. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date is Friday, November 20th. Regeneron Pharmaceuticals’s dividend payout ratio is currently 8.30%.

Insider Buying and Selling

In related news, EVP Joseph Larosa sold 4,466 shares of the firm’s stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $965.49, for a total value of $4,311,878.34. Following the sale, the executive vice president directly owned 38,906 shares of the company’s stock, valued at $37,563,353.94. This trade represents a 10.30% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Huda Zoghbi sold 7,439 shares of the business’s stock in a transaction dated Tuesday, November 3rd. The shares were sold at an average price of $970.46, for a total value of $7,219,251.94. Following the transaction, the director owned 1,703 shares in the company, valued at approximately $1,652,693.38. This represents a 81.37% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 27,028 shares of company stock valued at $25,025,950 over the last ninety days. Corporate insiders own 6.97% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently commented on REGN. Evercore increased their price objective on Regeneron Pharmaceuticals from $825.00 to $850.00 and gave the company an “outperform” rating in a research report on Friday, July 31st. Royal Bank Of Canada upped their target price on Regeneron Pharmaceuticals from $810.00 to $913.00 and gave the stock a “sector perform” rating in a research note on Monday, November 2nd. Zacks Research upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Monday, September 28th. Cantor Fitzgerald lifted their price target on shares of Regeneron Pharmaceuticals from $795.00 to $980.00 and gave the stock an “overweight” rating in a research note on Monday, November 2nd. Finally, Piper Sandler boosted their price objective on shares of Regeneron Pharmaceuticals from $854.00 to $865.00 and gave the stock an “overweight” rating in a report on Monday, October 19th. One investment analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $898.97.

Key Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Regeneron reported promising first-in-human results for CIDEBsiRNA, an investigational treatment being developed with Alnylam for metabolic-dysfunction-associated steatotic liver disease (MASLD). A single dose rapidly normalized liver fat and improved liver-injury markers in patients. The early results could strengthen the program’s prospects, though further study is needed. Alnylam Collaborator Regeneron Advances CIDEBsiRNA with Promising First-in-Human Results in Patients with MASLD
• Neutral Sentiment: Soleo Health was selected as a specialty-pharmacy partner for Pasatru, Regeneron’s recently approved treatment for the rare disorder FOP. The partnership may help facilitate access, but the report provided no sales or uptake figures. Soleo Health Selected as a Specialty Pharmacy Partner for Pasatru
• Neutral Sentiment: A comparison of Regeneron and Amgen highlighted Regeneron’s lack of net debt and faster growth, but it was an investor-oriented analysis, not a new company announcement. Amgen vs. Regeneron: Higher Dividends Now or Bigger Growth Later?
• Neutral Sentiment: A short-interest entry describes a significant increase but reports total short interest of zero shares, making the data internally inconsistent and not a reliable directional signal.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious diseases. Its research and product portfolio spans areas including eye disease, allergic and inflammatory conditions, cancer, cardiovascular and metabolic disorders, infectious diseases and rare conditions. The company’s medicines include EYLEA for certain eye diseases, Dupixent for inflammatory conditions and Libtayo for cancer. Regeneron also develops and markets treatments with pharmaceutical partners, including Sanofi, and its products reach patients in the United States and international markets through its own operations and collaborations.